ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) in a note issued to investors on Thursday,Benzinga reports. The firm set a "buy" rating and a $84.00 price target on the specialty pharmaceutical company's stock. HC Wainwright's target price indicates a potential upside of 28.62% from the stock's current price.

A number of other analysts have also issued reports on the company. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target on the stock. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Wall Street Zen downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Finally, Truist Financial upped their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a report on Monday, April 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $78.88.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $65.31 on Thursday. The company has a market cap of $1.41 billion, a PE ratio of -51.43 and a beta of 0.57. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $77.00. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66. The firm's 50 day moving average price is $63.56 and its 200-day moving average price is $62.10.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The business's quarterly revenue was up 43.4% on a year-over-year basis. During the same quarter last year, the company posted $0.82 earnings per share. Sell-side analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Christopher Mutz sold 4,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the completion of the transaction, the insider directly owned 107,317 shares of the company's stock, valued at $6,487,312.65. This represents a 3.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Ori Gutwerg sold 881 shares of the stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president directly owned 89,897 shares of the company's stock, valued at approximately $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,681 shares of company stock worth $346,854. 11.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently modified their holdings of the stock. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter worth $28,000. US Bancorp DE raised its holdings in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after buying an additional 531 shares in the last quarter. National Bank of Canada FI bought a new position in ANI Pharmaceuticals during the first quarter valued at about $79,000. GAMMA Investing LLC increased its stake in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 881 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals in the fourth quarter worth about $166,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.